



Pneumococcal Vaccine Update in Adults

The Advisory Committee on Immunization Practices (ACIP) recently released an updated report for the use of pneumococcal vaccines in adults aged 19 years and older. Notably, the report provides new recommendations for the use of either 20-valent pneumococcal conjugate vaccine (PCV20, *Prenar 20*) or at least one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23, *Pneumovax 23*) for adults who previously received 13-valent pneumococcal conjugate vaccine (PCV13, *Prenar 13*) only. The report also incorporates updated clinical guidance from the Centers for Disease Control and Prevention (CDC) recommending the use of either PCV20 or 15-valent pneumococcal conjugate vaccine (PCV15, *Vaxneuvance*) for adults who previously received PPSV23 only. A summary of the vaccine schedules is listed below.^{1,2}

Pneumococcal Vaccine Schedules for Adults Aged 65 Years and Older^{1,2}

Previous vaccine	Recommendations		
None, unknown or PCV7* only at any age	PCV20	OR	PCV15 followed by PPSV23 ≥ one year† after
PPSV23 only at any age	PCV20	OR	PCV15 ≥ one year after PPSV23
PCV13 only at any age	PCV20	OR	PPSV23 ≥ one year† after PCV13
PCV13 at any age and PPSV23 at < 65 years	PCV20 ≥ five years after last dose	OR	PPSV23 ≥ one year† after last PCV13 dose and ≥ five years after last PPSV23 dose
PCV13 at any age and PPSV23 at ≥ 65 years	May administer PCV20 at least five years after last dose through shared clinical decision-making		

*7-valent pneumococcal conjugate vaccine

†Consider minimum interval of eight weeks for adults with an immunocompromising condition, cerebrospinal fluid leak or cochlear implant

Pneumococcal Vaccine Schedules for Adults Aged 19 to 64 Years^{1,2}

Previous vaccine	Recommendations		
	Chronic medical condition*	Cerebrospinal fluid leak or cochlear implant	Immunocompromising condition†
None, unknown or PCV7 only	PCV20 OR PCV15 followed by PPSV23 ≥ one year after	PCV20 OR PCV15 followed by PPSV23 ≥ eight weeks after	
PPSV23 only	PCV20 ≥ one year after	OR	PCV15 ≥ one year after
PCV13 only	PCV20 ≥ one year after OR PPSV23 ≥ one year after	PCV20 ≥ one year after OR PPSV23 ≥ eight weeks after	PCV20 ≥ one year after OR two doses of PPSV23§
PCV13 and one dose of PPSV23	No further vaccination; review at age 65 years	PCV20 ≥ five years after last dose OR no further vaccination; review at age 65 years	PCV20 ≥ five years after last dose OR one dose of PPSV23§
PCV13 and two doses of PPSV23	N/A	N/A	PCV20 ≥ five years after last dose OR no further vaccination; review at age 65 years

*Chronic heart, lung or liver disease; alcoholism; diabetes mellitus; cigarette smoker

†Includes chronic renal failure, asplenia, generalized malignancy, HIV infection, Hodgkin disease, leukemia, lymphoma, multiple myeloma, sickle cell disease and solid organ transplant (refer to ACIP and CDC guidelines for a comprehensive list)

§The minimum interval for PPSV23 is ≥ eight weeks since last PCV13 dose and ≥ five years since last PPSV23 dose

References

1. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. *MMWR Recomm Rep* 2023;72(No. RR-3):1–39. DOI: <http://dx.doi.org/10.15585/mmwr.r7203a1>. Accessed September 19, 2023.
2. Centers for Disease Control and Prevention (CDC). Pneumococcal Vaccine Timing for Adults. Updated March 15, 2023. <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>. Accessed September 19, 2023.